These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 29464969)

  • 21. Clostridium difficile infection.
    Smits WK; Lyras D; Lacy DB; Wilcox MH; Kuijper EJ
    Nat Rev Dis Primers; 2016 Apr; 2():16020. PubMed ID: 27158839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microbiologic factors affecting Clostridium difficile recurrence.
    Chilton CH; Pickering DS; Freeman J
    Clin Microbiol Infect; 2018 May; 24(5):476-482. PubMed ID: 29208562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clostridium difficile and the disease it causes.
    Norén T
    Methods Mol Biol; 2010; 646():9-35. PubMed ID: 20597000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on Treatment of Clostridioides difficile Infection.
    Cho JM; Pardi DS; Khanna S
    Mayo Clin Proc; 2020 Apr; 95(4):758-769. PubMed ID: 32247350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clostridioides difficile (formerly Clostridium difficile) infection in the critically ill: an expert statement.
    Antonelli M; Martin-Loeches I; Dimopoulos G; Gasbarrini A; Vallecoccia MS
    Intensive Care Med; 2020 Feb; 46(2):215-224. PubMed ID: 31938827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. .Clostridioides difficile.
    Sandhu BK; McBride SM
    Trends Microbiol; 2018 Dec; 26(12):1049-1050. PubMed ID: 30297117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigational new treatments for Clostridium difficile infection.
    Ivarsson ME; Leroux JC; Castagner B
    Drug Discov Today; 2015 May; 20(5):602-8. PubMed ID: 25499664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel therapeutic strategies for Clostridium difficile infections.
    Ünal CM; Steinert M
    Expert Opin Ther Targets; 2016; 20(3):269-85. PubMed ID: 26565670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and Structure-Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of
    Rueedi G; Panchaud P; Friedli A; Specklin JL; Hubschwerlen C; Blumstein AC; Caspers P; Enderlin-Paput M; Jacob L; Kohl C; Locher HH; Pfaff P; Schmitt C; Seiler P; Ritz D
    J Med Chem; 2024 Jun; 67(11):9465-9484. PubMed ID: 38753983
    [No Abstract]   [Full Text] [Related]  

  • 30. Exploring ways to improve CDI outcomes.
    Galpérine T; Guery B;
    Med Mal Infect; 2018 Feb; 48(1):10-17. PubMed ID: 29336930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clostridioides difficile in transplant patients: early diagnosis, treatment, and prevention.
    Revolinski SL; Munoz-Price LS
    Curr Opin Infect Dis; 2019 Aug; 32(4):307-313. PubMed ID: 31116134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system.
    Meader E; Mayer MJ; Steverding D; Carding SR; Narbad A
    Anaerobe; 2013 Aug; 22():25-30. PubMed ID: 23685029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent developments in the management of recurrent Clostridioides difficile infection.
    Mendo-Lopez R; Villafuerte-Gálvez J; White N; Mahoney MV; Kelly CP; Alonso CD
    Anaerobe; 2020 Apr; 62():102108. PubMed ID: 31606481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-conventional antimicrobial and alternative therapies for the treatment of Clostridium difficile infection.
    Roshan N; Hammer KA; Riley TV
    Anaerobe; 2018 Feb; 49():103-111. PubMed ID: 29309845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bile salt hydrolase-mediated inhibitory effect of Bacteroides ovatus on growth of Clostridium difficile.
    Yoon S; Yu J; McDowell A; Kim SH; You HJ; Ko G
    J Microbiol; 2017 Nov; 55(11):892-899. PubMed ID: 29076071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibiotic-Induced Dysbiosis Predicts Mortality in an Animal Model of Clostridium difficile Infection.
    Burdet C; Sayah-Jeanne S; Nguyen TT; Hugon P; Sablier-Gallis F; Saint-Lu N; Corbel T; Ferreira S; Pulse M; Weiss W; Andremont A; Mentré F; de Gunzburg J
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Faecal microbiota transplantation for eradication of co-infection with
    Bahl MI; Jørgensen SMD; Skriver AH; Larsen NA; Wang M; Licht TR; Dahlerup JF; Hvas CL
    Scand J Gastroenterol; 2020 May; 55(5):626-630. PubMed ID: 32324085
    [No Abstract]   [Full Text] [Related]  

  • 38. New and emerging therapies in treatment of Clostridium difficile infection.
    Goyal H; Perisetti A; Rehman MR; Singla U
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):589-597. PubMed ID: 29521664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful therapy of Clostridium difficile infection with fecal microbiota transplantation.
    Konturek PC; Koziel J; Dieterich W; Haziri D; Wirtz S; Glowczyk I; Konturek K; Neurath MF; Zopf Y
    J Physiol Pharmacol; 2016 Dec; 67(6):859-866. PubMed ID: 28195066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection.
    Khanna S; Pardi DS; Kelly CR; Kraft CS; Dhere T; Henn MR; Lombardo MJ; Vulic M; Ohsumi T; Winkler J; Pindar C; McGovern BH; Pomerantz RJ; Aunins JG; Cook DN; Hohmann EL
    J Infect Dis; 2016 Jul; 214(2):173-81. PubMed ID: 26908752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.